Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets

被引：0
|
作者：
Kozma, Chris [1 ]
Evans, Emily [2 ]
Lebson, Lori [2 ]
Phillips, Amy [2 ]
Lobo, Carroline [2 ]
机构：
[1] CK Consulting Associates LLC, Baton Rouge, LA USA
[2] EMD Serono Inc, Rockland, MA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203948
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P14-3.001
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PATIENT CHARACTERISTICS AND PERSISTENCE AMONG COMMERCIALLY INSURED PATIENTS WITH MULTIPLE SCLEROSIS INITIATING CLADRIBINE TABLETS
    Kozma, C. M.
    Evans, E.
    Lebson, L.
    Phillips, A.
    Lobo, C.
    VALUE IN HEALTH, 2022, 25 (12) : S432 - S432
  • [2] Characteristics and Treatment Patterns of Patients with Multiple Sclerosis Initiating Cladribine Tablets in the United States
    Lobo, C.
    Lee, J.
    Chin, A.
    Lui, S.
    Chen, X.
    Evans, E.
    Phillips, A. L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 192 - 193
  • [3] Characteristics of US Commercially Insured Patients Initiating Tirzepatide for Obesity
    Hankosky, Emily
    Gibble, Theresa Hunter
    Chinthammit, Chanadda
    Mojdami, Donna
    Schapiro, David
    He, Xuanyao
    Venkataraman, Malvika
    Stockbower, Grace
    Grabner, Michael
    Desai, Karishma
    OBESITY, 2024, 32 : 115 - 116
  • [4] Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
    Goodin, Douglas S.
    Corwin, Michael
    Kaufman, David
    Golub, Howard
    Reshef, Shoshana
    Rametta, Mark J.
    Knappertz, Volker
    Cutter, Gary
    Pleimes, Dirk
    PLOS ONE, 2014, 9 (08):
  • [5] Comparison of compliance and persistence with immunomodulating agents for multiple sclerosis in a commercially insured population
    Shea, T.
    Wood, F.
    Shim, B.
    Becker, E.
    Meletiche, D.
    Bennett, R.
    AL-Sabbagh, A.
    VALUE IN HEALTH, 2008, 11 (03) : A144 - A145
  • [6] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [7] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [8] Trends for Healthcare Cost among Commercially Insured Individuals with Multiple Sclerosis
    Kim, Youngran
    Krause, Trudy
    Blum, Philip
    Freeman, Leorah
    NEUROLOGY, 2019, 92 (15)
  • [9] Incidence of infections and severe lymphopenia in patients newly initiating cladribine tablets or fingolimod for treatment of multiple sclerosis: CLARION study
    Hillert, J.
    Butzkueven, H.
    Soilu-Hanninen, M.
    Ziemssen, T.
    Kuhle, J.
    Berger, J. R.
    Aydemir, A.
    Sonajalg, J.
    Bezemer, I.
    Sabido, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 639 - 640
  • [10] The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
    Butzkueven, Helmut
    Hillert, Jan
    Soilu-Hanninen, Merja
    Ziemssen, Tjalf
    Kuhle, Jens
    Wergeland, Stig
    Magyari, Melinda
    Berger, Joseph R.
    Moore, Nicholas
    Aydemir, Aida
    Bezemer, Irene
    Sabido, Meritxell
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (10) : 1367 - 1374
12345